Evaluation of vancomycin use in late-onset neonatal sepsis using the area under the concentration-time curve to the minimum inhibitory concentration ≥400 target

Therapeutic Drug Monitoring

Volumn 37, Issue 6, 2015, Pages 756-765

  Bhongsatiern, Jiraganya ^a   Stockmann, Chris ^b,c   Roberts, Jessica K ^b   Yu, Tian ^b   Korgenski, Kent E ^d   Spigarelli, Michael G ^b,c   Desai, Pankaj B ^a   Sherwin, Catherine M T ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d INTERMOUNTAIN HEALTHCARE   (United States)

Author keywords

Late onset sepsis; MRSA; Neonates; Pharmacodynamic target; Vancomycin

Indexed keywords

CREATININE; VANCOMYCIN; ANTIINFECTIVE AGENT;

AREA UNDER THE CURVE; ARTICLE; BACTERIUM CULTURE; BLOOD SAMPLING; BODY WEIGHT; COAGULASE NEGATIVE STAPHYLOCOCCUS; COHORT ANALYSIS; COMPARTMENT MODEL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEMOGRAPHY; DRUG MONITORING; DRUG USE; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NEWBORN; NEWBORN SEPSIS; OBSERVATIONAL STUDY; PLASMA CONCENTRATION-TIME CURVE; PREMATURITY; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; STAPHYLOCOCCAL BACTEREMIA; VOLUME OF DISTRIBUTION; BIOLOGICAL MODEL; DOSE RESPONSE; INFANT, NEWBORN, DISEASES; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; NONLINEAR SYSTEM; SEPSIS; STAPHYLOCOCCAL INFECTIONS; TISSUE DISTRIBUTION;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; MALE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; RETROSPECTIVE STUDIES; SEPSIS; STAPHYLOCOCCAL INFECTIONS; TISSUE DISTRIBUTION; VANCOMYCIN;

EID: 84947908062     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000216     Document Type: Article

References (49)

1. Hornik CP, Fort P, Clark RH, et al. Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units. Early Hum Dev. 2012;88(suppl 2):S69-S74.
2. Camacho-Gonzalez A, Spearman PW, Stoll BJ. Neonatal infectious diseases: evaluation of neonatal sepsis. Pediatr Clin North Am. 2013;60:367-389.
3. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110:285-291.
4. Clark R, Powers R, White R, et al. Nosocomial infection in the NICU: a medical complication or unavoidable problem? J Perinatol. 2004;24: 382-388.
5. Baltimore RS. Neonatal sepsis: epidemiology and management. Paediatr Drugs. 2003;5:723-740.
6. Edwards MS, Baker CJ. Bacterial infections in the neonate. In: Long SS, Pickering LK, Prover C, eds. Principles and Practice of Pediatric Infections Diseases. Philadelphia, PA: Elsevier Saunders; 2012:538-544.e532.
7. American Academy of Pediatrics. Staphylococcal infections. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book: 2012 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2012:809.
8. Stockmann C, Spigarelli MG, Campbell SC, et al. Considerations in the pharmacologic treatment and prevention of neonatal sepsis. Paediatr Drugs. 2014;16:67-81.
9. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. CLSI Approved Standard M100-s16. Wayne, PA: Clinical and Laboratory Standards Institute; 2006.
10. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009;49:325-327.
11. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18-e55.
12. Schwartz GJ, Munoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20:629-637.
13. Allegaert K, Kuppens M, Mekahli D, et al. Creatinine reference values in ELBW infants: impact of quantification by Jaffe or enzymatic method. J Matern Fetal Neonatal Med. 2012;25:1678-1681.
14. Zhao W, Kaguelidou F, Biran V, et al. External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings. Br J Clin Pharmacol. 2012; 74:1068-1080.
15. Allegaert K, van den Anker JN. Creatinine-based vancomycin dosing regimens in neonates: there is more to consider than the variation in drug assay. Pharmacotherapy. 2012;32:e174; discussion e175.
16. Neuman G, Nulman I, Adeli K, et al. Implications of serum creatinine measurements on GFR estimation and vancomycin dosing in children. J Clin Pharmacol. 2014;54:785-791.
17. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-S266.
18. Seay RE, Brundage RC, Jensen PD, et al. Population pharmacokinetics of vancomycin in neonates. Clin Pharmacol Ther. 1994;56:169-175.
19. Capparelli EV, Lane JR, Romanowski GL, et al. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J Clin Pharmacol. 2001;41:927-934.
20. Kimura T, Sunakawa K, Matsuura N, et al. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob Agents Chemother. 2004;48:1159-1167.
21. Anderson BJ, Allegaert K, Van den Anker JN, et al. Vancomycin phar-macokinetics in preterm neonates and the prediction of adult clearance Br J Clin Pharmacol. 2007;63:75-84.
22. Allegaert K, Anderson BJ, van den Anker JN, et al. Renal drug clearance in preterm neonates: relation to prenatal growth. Ther Drug Monit. 2007; 29:284-291.
23. Lo YL, van Hasselt JG, Heng SC, et al. Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination. Antimicrob Agents Chemother. 2010;54:2626-2632.
24. Marques-Minana MR, Saadeddin A, Peris JE. Population pharmacoki-netic analysis of vancomycin in neonates. A new proposal of initial dosage guideline. Br J Clin Pharmacol. 2010;70:713-720.
25. De Cock RF, Allegaert K, Brussee JM, et al. Simultaneous pharmacoki-netic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. Pharm Res. 2014;31:2643-2654.
26. De Cock RF, Allegaert K, Sherwin CM, et al. A neonatal amikacin co-variate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. Pharm Res. 2014;31:754-767.
27. Frymoyer A, Hersh AL, El-Komy MH, et al. Association between van-comycin trough concentration and AUC in neonates. Antimicrob Agents Chemother. 2014;58:6454-6461.
28. Le J, Bradley JS, Murray W, et al. Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J. 2013;32:e155-e163.
29. Le J, Vaida F, Nguyen E, et al. Population-based pharmacokinetic modelling of vancomycin in children with renal Insufficiency. J Pharmacol Clin Toxicol. 2014;2:1017-1026.
30. Pacifici GM, Allegaert K. Clinical pharmacokinetics of vancomycin in the neonate: a review. Clinics (Sao Paulo). 2012;67:831-837.
31. Marsot A, Boulamery A, Bruguerolle B, et al. Vancomycin: a review of population pharmacokinetic analyses. Clin Pharmacokinet. 2012;51:1-13.
32. Jonsson EN, Karlsson MO. Xpose-an S-PLUS based population phar-macokinetic/pharmacodynamic model building aid for NONMEM. Com-put Methods Programs Biomed. 1999;58:51-64.
33. Beal SL, Sheiner LB. NONMEM User's Guides. San Francisco, CA: University of California; 1989.
34. Moise-Broder PA, Forrest A, Birmingham MC, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43:925-942.
35. Counahan R, Chantler C, Ghazali S, et al. Estimation of glomerular filtration rate from plasma creatinine concentration in children. Arch Dis Child. 1976;51:875-878.
36. Leger F, Bouissou F, Coulais Y, et al. Estimation of glomerular filtration rate in children Pediatr Nephrol. 2002;17:903-907.
37. Grimsley C, Thomson AH. Pharmacokinetics and dose requirements of vancomycin in neonates. Arch Dis Child Fetal Neonatal Ed. 1999;81: F221-F227.
38. de Hoog M, Schoemaker RC, Mouton JW, et al. Vancomycin population pharmacokinetics in neonates. Clin Pharmacol Ther. 2000;67:360-367.
39. Mehrotra N, Tang L, Phelps SJ, et al. Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations. Pharmacotherapy. 2012;32:408-419.
40. van den Anker JN, de Groot R, Broerse HM, et al. Assessment of glo-merular filtration rate in preterm infants by serum creatinine: comparison with inulin clearance. Pediatrics. 1995;96:1156-1158.
41. Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2013;2:e38.
42. Weisman LE. Coagulase-negative staphylococcal disease: emerging therapies for the neonatal and pediatric patient. Curr Opin Infect Dis. 2004; 17:237-241.
43. Center KJ, Reboli AC, Hubler R, et al. Decreased vancomycin susceptibility of coagulase-negative staphylococci in a neonatal intensive care unit: evidence of spread of Staphylococcus warneri. J Clin Microbiol. 2003;41:4660-4665.
44. Frymoyer A, Hersh AL, Benet LZ, et al. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J. 2009;28:398-402.
45. Campbell ML, Marchaim D, Pogue JM, et al. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 mcg/mL to vancomycin: old (trimethoprim/sulfame-thoxazole) versus new (daptomycin or linezolid) agents. Ann Pharmac-other. 2012;46:1587-1597.
46. Nelson JD, Bradley JS. Antimicrobial therapy for newborns. In: Kimberlin DW, Leake JAD, Palumbo PE, et al, eds. Nelson's Pediatric Antimicrobial Therapy. Elk Grove Village, IL: American Academy of Pediatrics; 2012-2013:35.
47. Young T, Mangum B. Antimicrobials. Neofax: A Manual of Drug Used in Neonatal Care. Montvale, NJ: Thomson Reuters; 2011:102-103.
48. Srivastava T, Alon US, Althahabi R, et al. Impact of standardization of creatinine methodology on the assessment of glomerular filtration rate in children Pediatr Res. 2009;65:113-116.
49. Holmes NE, Turnidge JD, Munckhof WJ, et al. Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bac-teremia. Antimicrob Agents Chemother. 2013;57:1654-1663.